When submitting, the first author must agree to register and present the abstract at the Meeting if it is selected for presentation. This includes being present during the scheduled time of a poster session. The first author may delegate an alternate presenter to attend in person if they are n...
Individuals may submit an unlimited number of Trials in Progress abstracts. 个人可以提交无限数量的进行中的试验摘要。Guidelines for Trials in Progress submissions are availablehere. ASCO membership is not required to submit an abstract, however, each abstract must be sponsored by an ASCO member. 每份...
in which oncologists agree to follow guidelines-driven treatment regimens agreed upon by consensus of their academic center, health plan, or practice network; (2) therapeutic interchanges, in which reimbursement models create incentives to promote lower-cost drugs, such as biosimilars; and (3) appr...
在本次盛会中,来自东南大学附属中大医院沈杨教授团队的“安罗替尼治疗晚期妇科肿瘤的有效性和安全性:一项真实世界研究”(Efficacy and safety of anlotinib in overall and disease-specific advanced gynecological cancer: A real-world stu...
8、Schwendenwein A, et al. Mol Ther Oncolytics. 2021;20:470-483. 9、Gay CM et al. Cancer Cell. 2021 Mar 8; 39(3): 346–360. 10、Xie M, et al. 2022 AACR, Abs#CT024. 11、Sukhvinder Johal, et al. at ...
47.9%, 47.0%, and 5.1% of abstracts were accepted as online publication only, poster, and oral presentation, respectively. First authors were affiliated with institutions in native English-speaking countries (NESC) in 83 (70.9%) abstracts and non-native English-speaking countries (NNESC) in 34...
[4] Joshua Z. Drago, Fresia Pareja, Komal L. Jhaveri et al. HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.Poster 1052 BREAST CANCER—METASTATIC.ASCO 2023. [5] Unraveling the mechanism of action and resistance to Trastuzumab deruxtecan (T-DXd): biomarker ...
Poster Session 前列腺癌 01 摘要号:47 The comparison of clinical utility between pan-cancer panel and PCa-specific panel for mCRPC 讲者:董柏君 上海交通大学医学院附属仁济医院 02 摘要号:78 The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-...
[4] Joshua Z. Drago, Fresia Pareja, Komal L. Jhaveri et al. HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers.Poster 1052 BREAST CANCER—METASTATIC.ASCO 2023. [5] Unraveling the mechanism of action and resistance to Trastuzumab deruxtecan (T-DXd): biomarker ...
【Poster Discussion Session 1022】 探索HER2- mBC 不同ADC治疗排兵布阵,支持T-DXd前线使用 ADC已成为针对HER2低表达乳腺癌治疗的研究热点,目前FDA 已批准T-DXd用于HER2低表达mBC、戈沙妥珠单抗(SG)用于HER2阴性 mBC治疗,本次ASCO大会上也更新了针对HR+患者的TROPiCS02研究中SG(Trop2 ADC)对比TPC在HER2低表达亚...